Clinical trials: Lipid Disorders
Hypertriglyceridemia, Hyperlipoproteinemia Type IV
Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients
The primary purpose of this trial is to determine if the treatment with rosuvastatin 10 and 20mg/day during 8 weeks in hypertriglyceridemic patients will reduce their triglyceride levels.
- Conditions
- Hypertriglyceridemia, Hyperlipoproteinemia Type IV, Hyperlipoproteinemia Type V, Hyperlipoproteinemia Type IIb
- Trial name
- NCT00473655
- Testing
- rosuvastatin
- Where
- 3 sites in Mexico
- Volunteers
- 334 people
- Sponsor
- AstraZeneca
Hypercholesterolemia, Dyslipidemia
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
The primary objective of this study is to evaluate the safety and tolerability of repeated doses of PF-04950615 (RN316) in study volunteers with hypercholesterolemia.
- Trial name
- NCT01243151
- Testing
- PF-04950615 (RN316)
- Where
- 9 sites in United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity, Visceral, Cardiovascular Diseases
Impact of Liraglutide 3.0 on Body Fat Distribution
This study is a clinical study to investigate the efficacy of liraglutide compared to placebo in reducing visceral adiposity measured by MRI in overweight or obese subjects at high risk for cardiovascular disease after 40 weeks…
- Conditions
- Obesity, Visceral, Cardiovascular Diseases, Fat Disorder
- Trial name
- NCT03038620
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 235 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Hypercholesterolemia
Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo
The main purpose of this study is to evaluate the effect on mental state (known as "neurocognitive function") with use of Praluent.
- Trial name
- NCT02957682
- Testing
- Praluent (Alirocumab)
- Where
- 188 sites in United States, Bulgaria and 7 more
- Volunteers
- 2,176 people
- Sponsor
- Regeneron Pharmaceuticals
Atherosclerosis, Low-density Lipoproteins Aggregation Susceptibility
The Effect of E-EPA on Circulating LDL and Plasma Lipid Metabolism
40-70 healthy volunteers of ages 18 to 65 participate in a E-EPA-diet where 3,9 grams of E-EPA is added to their normal diet and lifestyles for a month.
- Conditions
- Atherosclerosis, Low-density Lipoproteins Aggregation Susceptibility, Low-density Lipoprotein Lipid Composition, Cardiovascular Diseases
- Trial name
- EPA&LDL (NCT04152291)
- Testing
- Ethyl-Eicosapentaenoic Acid (E-EPA)
- Where
- Finland
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Wihuri Research Institute
Body Fat Disorder
CoolSculpting and EMS for the Abdomen
Evaluate the use of Electromagnetic Muscle Stimulation as an adjunctive treatment to CoolSculpting.
- Trial name
- ECA (NCT03738891)
- Testing
- Zeltiq CoolSculpting System alone, Electromagnetic Muscle Stimulation alone, EMS followed by CoolSculping
- Where
- 4 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Zeltiq Aesthetics
Cardiovascular Disease
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and…
- Trial name
- SPIRE-1 (NCT01975376)
- Testing
- bococizumab (PF-04950615)
- Where
- 1,745 sites in United States, Argentina and 34 more
- Volunteers
- 16,784 people
- Sponsor
- Pfizer
Dyslipidemias
Effects of Lentinula Edodes Bars on Dyslipidemia and Oxidative Stress in Cholesterol Individuals: Randomized Study
The daily change in population routine has stimulated the development of health beneficial value added products. Lentinula edodes (Shiitake) is a mushroom with high protein concentration, low lipid content, rich in fiber…
- Trial name
- NCT04186780
- Testing
- Shiitake cereal bar
- Where
- Brazil
- Volunteers
- 68 people
- Sponsor
- University of Sorocaba
Hypertriglyceridemia, Cardiovascular Disease
[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL
The primary objective is to evaluate the efficacy of adding Epanova (2 g or 4 g daily) to an optimal statin monotherapy for lowering non-high-density lipoprotein (non-HDL) cholesterol in subjects with persistent…
- Trial name
- ESPRIT (NCT01408303)
- Testing
- Olive oil, 4g, omega-3-carboxylic acids, 2g, omega-3-carboxylic acids, 4g
- Where
- 89 sites in United States
- Volunteers
- 646 people
- Sponsor
- AstraZeneca
Dyslipidemia
A Study to Evaluate MK1903 in Patients With Dyslipidemia (MK1903-004)
This study will evaluate the lipid-modifying effect and tolerability of MK1903 when compared to placebo in patients with dyslipidemia who are not on a statin or other lipid-modifying therapy.
- Trial name
- NCT00847197
- Testing
- MK1903
- Volunteers
- 191 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia
A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)
This study will evaluate the efficacy and safety of MK-0653C (Ezetimibe [EZ] 10 mg/Atorvastatin [Atora] 10mg or 20 mg) compared to EZ 10 mg, Atora 10 mg, or Atora 20 mg alone when administered to Japanese participants with…
- Trial name
- NCT02550288
- Testing
- Ezetimibe 10 mg, Atorvastatin 10 mg, Diet control/Daily Exercise
- Volunteers
- 309 people
- Sponsor
- Organon and Co
Dyslipidemia
Study to Investigate the Efficacy and Pharmacokinetic Profile of K-877-ER Compared to K-877-IR
A study to evaluate the efficacy of K-877 extended release (ER) once daily (QD) compared to K-877 immediate release (IR) twice daily (BID).
- Trial name
- NCT04447820
- Testing
- K-877-ER (Dose A), K-877-ER (Dose B), K-877-IR
- Where
- 12 sites in United States
- Volunteers
- 96 people
- Sponsor
- Kowa Research Institute, Inc.
Dyslipidemia
12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia
The current study is designed to test the long-term (12-month) safety and efficacy of LCP-AtorFen, a combination of atorvastatin and fenofibrate, in patients with dyslipidemia
- Trial name
- NCT00664859
- Testing
- LCP-AtorFen
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Veloxis Pharmaceuticals
Fatigue, End Stage Renal Disease (ESRD)
Lipid Infusion in Dialysis Patients With Endotoxemia
The purpose of this study is to determine whether a phospholipid emulsion is effective in the treatment of chronic endotoxemia in hemodialysis patients.
- Trial name
- LIPIDOSE (NCT00506454)
- Testing
- Lipidose
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Sepsicure
Hyperlipidemia
LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2
The primary objective was to evaluate the effect of 12 weeks of evolocumab administered subcutaneously every 2 weeks (Q2W) and monthly (QM) when used in combination with a statin, compared with placebo, on percent change from…
- Trial name
- LAPLACE-2 (NCT01763866)
- Testing
- Evolocumab, Ezetimibe, Atorvastatin
- Where
- 244 sites in United States, Australia and 19 more
- Volunteers
- 2,067 people
- Sponsor
- Amgen
Primary Hypercholesterolemia, Mixed Hyperlipidemia
A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)
This is a 3-period study. Periods 1 and 2 will evaluate the effects of multiple doses of laropiprant on the antiplatelet effects of clopidogrel and aspirin administered in combination in participants with primary…
- Trial name
- NCT01012219
- Testing
- niacin (+) laropiprant, Comparator: aspirin, Comparator: clopidogrel
- Volunteers
- 36 people
- Sponsor
- Merck Sharp & Dohme LLC
Hyperlipidemia
Compliance With Treatment For Patients With Hyperlipidemia
It is a prospective observational study. Patients will be high risk patients (for developing cardiovascular events) that are treated with a statin.
- Trial name
- COLL (NCT00828945)
- Testing
- Lipid Self Test
- Where
- 17 sites in Sweden
- Volunteers
- 259 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Type 2 Diabetes Mellitus
Colesevelam for Children With Type 2 Diabetes
This study will evaluate the efficacy and safety of the study drug in treating type 2 diabetes in children 10 to 17 years old. The groups will be low-dose (0.625 g Welchol) and high-dose (3.75 g Welchol).
- Trial name
- WELKid DM (NCT01258075)
- Testing
- High-dose colesevelam, Low-dose colesevelam
- Where
- 24 sites in United States
- Volunteers
- 236 people
- Sponsor
- Daiichi Sankyo
Gaucher Disease
Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial
Gaucher disease, the most prevalent lysosomal storage disorder, is caused by mutations in the human glucocerebrosidase gene (GCD) leading to reduced activity of the lysosomal enzyme glucocerebrosidase and thereby to the…
- Trial name
- NCT00705939
- Testing
- Taliglucerase alfa
- Where
- 11 sites in United States, Australia and 6 more
- Volunteers
- 45 people
- Sponsor
- Pfizer
Cardiovascular Disease (CVD), Hypertension
Veteran Peer Coaches Optimizing and Advancing Cardiac Health
The purpose of this study is to test if having a Veteran peer health coach will improve blood pressure control among Veterans with high blood pressure and at least one other Cardiovascular disease (CVD) risk factor.
- Conditions
- Cardiovascular Disease (CVD), Hypertension, Hyperlipemia, Obesity
- Trial name
- Vet-COACH (NCT02697422)
- Testing
- Community-based peer health coach intervention
- Where
- United States
- Volunteers
- 264 people
- Sponsor
- VA Office of Research and Development